Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, UBS Group Analyst Says

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by analysts at UBS Group from $70.00 to $96.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price target points to a potential upside of 6.95% from the stock’s current price.

Several other equities research analysts have also issued reports on GILD. Truist Financial boosted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday. Robert W. Baird raised their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Finally, Oppenheimer raised their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Price Performance

GILD stock traded up $1.13 during mid-day trading on Thursday, hitting $89.76. The company had a trading volume of 4,057,263 shares, compared to its average volume of 7,092,298. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average price of $87.15 and a 200 day moving average price of $76.52. The company has a market capitalization of $111.87 billion, a price-to-earnings ratio of 997.33, a P/E/G ratio of 2.72 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.29 EPS. On average, research analysts anticipate that Gilead Sciences will post 4.38 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 56,947 shares of company stock worth $4,968,674. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently bought and sold shares of GILD. SkyView Investment Advisors LLC boosted its holdings in Gilead Sciences by 5.4% in the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock valued at $711,000 after purchasing an additional 435 shares during the period. Tri Ri Asset Management Corp acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $3,163,000. Westside Investment Management Inc. boosted its stake in Gilead Sciences by 3.5% in the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock valued at $2,249,000 after acquiring an additional 917 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of Gilead Sciences by 3.6% in the 3rd quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company’s stock valued at $807,000 after purchasing an additional 333 shares during the period. Finally, TD Private Client Wealth LLC boosted its holdings in shares of Gilead Sciences by 10.6% in the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company’s stock valued at $4,822,000 after acquiring an additional 5,497 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.